Eden Research Share Discussion Threads

[supersonico] 07/9/2019 20:28

My guess is the share price is good for Mrs100K, New York and Good for any strategic investor..not so great for PI's. IMO Eden are happy to have the share price @10p right now.

They certainly prefer 10p to 14.05p IMHO and the Cenkos report keeps the Anchor firmly in place.

[investingisatrickygame] 07/9/2019 19:30

Neither Cenkos, nor the Company.

Shifting gears, in short order and more have just been poor adjectives in relation to the share price.

People have to understand that when you are a plc the share price should always reflect the value of the company. This is what a listing does for you.

Forget the rhetoric. Is Eden worth just £20.7 million as we stand today?

If yes, then fine, if not, then management must try harder. Shareholders need to be respected and valued and so does their investment.

[supersonico] 07/9/2019 18:54

Did the Cenkos note adequately relay the 'Shifting Gears' ..' amongst the leaders in our industry.' sentiment started here?

I am confident that Eden’s prospects are bright, and we remain focussed on a programme of prudent financial management coupled with well-informed decision making and timely execution. Over the past few years it has been reported that the Company has ‘shifted gears’, and this is an apt metaphor. Continuing this theme, I am looking forward to building speed and positioning Eden to be amongst the leaders in our industry.
S M Smith Chief Executive Officer
19 March 2018

[investingisatrickygame] 07/9/2019 18:42

Arguably yes, based on past performance then no.

What is Cenkos going to do to unfold the story properly and is Eden going to play ball, be obedient and help them?!

[supersonico] 07/9/2019 17:57

Investing,

What happens next is anyone's Guess.

[investingisatrickygame] 07/9/2019 16:27

Super,

No share price activity to the positive since the report was produced. I would like to understand what Cenkos hoped to achieve from this initiation and over what time frame based on its 50+ pages and the price targets as is.

Has Cenkos taken this to its institutional clients and if so, with what response? How has it been received? How do you go to an institution when the price is 10p, the target is 12p and the spread that is in play on this stock and then, how that changes with volume. Is volume even available on the open market? If not and it won't be, what was the purpose of approaching said institutions when no stock is available in the quantities they would want to trade in and at such a dismal price target.

This can only mean one of a few things

1) Cenkos doesn't know what they're doing 9hopefully not)
2) Institutions will continue to sit on the sidelines until Eden proves itself (in their eyes) and then will only invest when the stock has traction and a suitable market cap
3) Reliance will therefore rest with private investors to lift the price to a suitable level, but the Company is not interested in motivating them and showing them value
4) The share price stay pretty much where it is until there is an event that more naturally underpins value in Eden and takes it there
5) Institutions then step in and support the share price

[supersonico] 07/9/2019 12:59

That be a No then I take it?

Pm me a email I'll send it on to you if you wish.

[brucie5] 07/9/2019 12:41

I haven't read the Cenkos report. Do you want me to post your question on MW?

[supersonico] 07/9/2019 08:46

Brucie5.

Has anyone one noticed the disconnect between Eden's AGM report and the Cenkos Report on Molluscicide and 3 out of 4 TT products missing from the vertical?

[weyweyumfozo] 07/9/2019 08:34

I thought that they had already done something about it - they gave themselves big pay rises.

[astralvision] 07/9/2019 00:37

Easy least, just reprice the options, problem sorted!

[investingisatrickygame] 06/9/2019 23:09

No options are going to be taken up at the end of this month then. They have fallen way short.

To be fair, they must be disappointed, but then again, they have to look at themselves and ask why the investor audience is not motivated to buy shares in Eden and finally review, what they can and will do about it.

[brucie5] 06/9/2019 21:30

Haven't heard back from him on the MW site- unless I've missed it

[supersonico] 06/9/2019 09:39

Brucie5

A while back you suggested I contact SS as 'Hastings on the MW site was able to do' and feedback.

With something as substantial as 3/4 of TT and a Molluscicide 4/5 years in development disappearing can you tell me how Hastings investigations into these blatant omissions are progressing?

[supersonico] 06/9/2019 09:06

Indeed it's an expensive process which an Eden partner started with Molluscicide around 2015 reporting a 'small trial'. It appeared in 2019 report along side Fungicide/ Nematicide /Insecticide on page 11 of the AGM presentation.



Now it's gone with no explanation as to it's whereabouts just like 3/4 of the TT vertical. Perhaps they have all joined CAP and SustainE down the black hole parallel delay Sofa at Eden short order HQ.

[brucie5] 06/9/2019 08:22

According to Eden, cost of developing a new biopesticide, 25-50m USD.

[bjlk] 05/9/2019 10:43

Couldn't agree more... they seem to think all talk is ok... meteoric jam tomorrow!!

[supersonico] 05/9/2019 08:33

Since Lykele as Chair is charged with ensuring Transparency and half year results should be this month, so let's see what the Chairman says this time around regarding the missing molluscicide.

It has been described as being 'developmental' for many years and is featured in the 2019 Annual report but Cenkos in a report commissioned by Eden completely missed it.

What is intriguing is it's disappearance at the very same time that Metaldehyde ban is on the horizon with The government saying that outdoor use of Metaldehyde must end by spring 2020.

So just as TT disappears in the face of an epidemic of Super head lice we find Eden's Developmental Molluscicide disappears as the demand is amplified for an alternative. So who is the partner ready to commercialise it?

Bayer is on the list of disappeared to.. along with SustainE.

Where are they all going??

[supersonico] 04/9/2019 09:01

I think that's very hard to do with Mevalone given the shifting picture of expanding applications / organic and growing territories / regulatory trends.

Cedroz ..same again as it's replacing Eastmans conventional market who's size we don't really know as they don't give granular details. Also the market is potentially bigger due to Organic opportunity I believe.

Having said that I have no faith in Cenkos projections. I consider them simplistic and unrealistic and given what I said about Mevalone Past sales or growth of sales cannot be used as a sensible basis for future growth estimates imo.

The best indicator of future growth is New York + Chase 7% / Mrs 100K / Director pay/ Director buys

The worst indicator of future growth. Cenkos KI4NY / what Directors Say.

[brucie5] 04/9/2019 08:46

I guess while we wait for revenues to build on back of MeV/Cedroz, it might be worth considering what the takeout value is likely to be for each of these, given sums and time invested. Then compare to mcap.

Reason jak is very wide of the mark. Even if the so is endlessly treading water.

[supersonico] 04/9/2019 08:15

Sipcam 3logy/ Araw Organic/ biopesticide market opportunity.. news

China adds 2967 pesticides MRLs in the latest national food standard, most of which were for minor crops, animal-sourced commodities and imported food. China will accelerate pesticide dietary risk assessment based on local residue trials, the most recent toxicological and dietary data and 10,000 MRLs would be implemented by 2020.


………………

By exercising its option, and following Eden's receipt of the €0.9m option exercise fee, Sipcam will be appointed exclusive distributor of Eden's first fungicide product, known as Mevalone, in the USA, Brazil, Mexico, China, Argentina, Chile, Japan, and South Africa. Mevalone, which is currently sold throughout Europe and in Kenya, will be marketed by Sipcam following receipt of the requisite approvals in each country. Eden recently announced the appointment of Sipcam as its exclusive distributor of Mevalone in Australia and New Zealand, thereby bringing the total number of countries in which Sipcam is Eden's distributor to twelve. Sipcam is already the exclusive distributor of Mevalone in Italy and Spain (where it is sold as 3logy® and Araw®, respectively), and therefore has good product knowledge and insight into the grape fungicide market, making it well-positioned to commercialise Mevalone in new markets.

The new distribution agreements covering China and Japan will mark Eden's first entry into the Far East and presents a significant opportunity as China is the largest grower of grapes in the world.


…………



The total market size for organic packaged food and beverages in China in 2017 is US$2,839.2mn. The country ranks as the 4th largest market in the world by value.
Per capita spending on organic packaged foods and beverages in China is US$2.050, which is the 32nd largest spending per capita in the world.

The largest company by sales in organic packaged food and beverages is Inner Mongolia Yili, which maintains 29.1% of total sales. It is followed by China Mengniu Dairy Co and Inner Mongolia Shengmu.
Organic packaged food and beverages in China will see strong year-on-year growth of close to 20% in 2018. This is higher than the rest of the Asia Pacific region, which will experience greater than 10% year-on-year growth in 2018.

[investingisatrickygame] 03/9/2019 15:24

Super,

I agree. I'm simply asking should Eden even comment on something that is not in their control? Why make statements about/on behalf of others that you have no control over, are not critical to your revenue model and streams and therefore, if the narrative is not delivered, can only reflect badly on your own judgement and statements made as you rightly point out.

You only have to look at JakNife who is uber critical and TT has been a vehicle for that poster and others.

Don't put TT (as an example)in the shop window if it isn't yours to sell.(I bet TT as a privately held company doesn't get the public stick that Eden does for the same subject).